Log in to search using one of your social media accounts:

 

Here's how Bright Health fared in its first big-market test
Despite an $18 million loss in Colorado, company officials are happy how the venture-capital-backed startup performed there. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 18, 2018 Category: Biotechnology Source Type: news

TBJ names Pappas as 2018 Life Sciences Awards Lifetime Achievement Award winner
Art Pappas has amassed a 30-plus-year career that includes operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life sciences companies. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 18, 2018 Category: Health Management Authors: Cameron Snipes Source Type: news

TBJ names Pappas as 2018 Life Sciences Awards Lifetime Achievement Award winner
Art Pappas has amassed a 30-plus-year career that includes operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life sciences companies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 18, 2018 Category: Biotechnology Authors: Cameron Snipes Source Type: news

Mass. medical device industry sees growth in VC funding, PMA approvals
Venture capital funding, PMA approvals and granted patents grew for Massachusetts-based medical device companies last year, according to a new report from firm Grant Thornton. The report, presented by managing principal George Serafin at MassMedic’s annual meeting, found that the Bay State’s medical device sector is second only to California for VC funding – reeling in $3.7 billion between 2014 and 2017. Massachusetts is also ranked just behind California for the most approved medical device patents, garnering 7% of total approvals in the U.S. The number of 510(k) applications approved in the Commonwealth...
Source: Mass Device - April 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Wall Street Beat MassMEDIC Source Type: news

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing
Funding to support Phase 2 clinical trials of the company's PSGL-1 inhibitor, SelK2, in multiple indications OKLAHOMA CITY, April 18, 2018 -- (Healthcare Sales & Marketing Network) -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical c... Biopharmaceuticals, Venture Capital Tetherex Pharmaceuticals, venous thromboembolism, PSGL-1, SelK2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2018 Category: Pharmaceuticals Source Type: news

Medical Microinstruments S.p.A. Announces €20M in Series A Funding to Advance Its Robotic Platform for Microsurgery
CALCI, Italy, April 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medical Microinstruments S.p.A. (MMI), an Italian company dedicated to improve clinical outcomes for patients undergoing microsurgery, today announces the completion of a €20M (appr... Devices, Surgery, Venture Capital Medical Microinstruments, robotic surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2018 Category: Pharmaceuticals Source Type: news

Mass. medical device companies see gains in VC funding, jobs
The report, which will be presented on Wednesday at the annual meeting of industry trade group MassMedic, shows that Massachusetts-based medical device companies snared more than $5 billion in venture capital investments between 2010 and 2017. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 18, 2018 Category: American Health Authors: Max Stendahl Source Type: news

How to protect your medtech startup ’s innovations
Building a strategic patent portfolio is crucial to success for a medtech startup.  David J. Dykeman, Greenberg Traurig [Image from Unsplash]When it comes to starting and building a medical device company, a strong patent strategy tied to business goals can be the driving force behind venture capital investment, strategic collaborations, and mergers and acquisitions. In order to safeguard its intellectual property (IP), every medtech startup should consider these five tips for protecting and leveraging its innovations. 1. File early and file often Fundamental to a strong patent portfolio is establishing solid patent p...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: Legal News Patent Infringement Research & Development Greenberg Traurig intellectualproperty patents startups Source Type: news

LimFlow raises $34m in Series C round
LimFlow said today it raised $33.5 million (EU €27 million) in an oversubscribed Series C round of financing to support its technology designed to treat critical limb ischemia. The round was led by Sofinnova Partners and joined by existing investors BpiFrance and Balestier, the Paris-based company said. As part of the funding round, Sofinnova venture partner Gérard Hascöet and Soffinova Crossover I fund partner Dr. Kinam Hong will join LimFlow’s board of directors. “LimFlow is an excellent fit for our healthcare Crossover I fund, where we seek investments in companies with game-changing technol...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Vascular LimFlow Source Type: news

TELA Bio Announces Series B Investment by Checkmate Capital
Surgical reconstruction company looks to forge long-term relationship with strategic investment group. MALVERN, Pa., April 16, 2018 -- (Healthcare Sales & Marketing Network) -- TELA Bio®, Inc., a surgical reconstruction company leading the developm... Devices, Surgery, Venture Capital TELA Bio, OviTex, Reinforced BioScaffolds (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 16, 2018 Category: Pharmaceuticals Source Type: news

How To Walk the Innovation Walk (Not Just Talk the Talk)
In an industry led by the likes of Medtronic, Boston Scientific,  Abbott, and Edwards Lifesciences,  there's a popular notion that innovation doesn't happen at large public companies, it happens at small startups that large companies try to buy in an effort to grow inorganically. That's not necessarily true.  As many industry thought leaders have explored, big medtech companies can still innovate at a startup pace. But an expert who spoke at the Design of Medical Devices Conference in Minneapolis last week says these companies have to learn to approach innovation differently in order to be successful. "...
Source: MDDI - April 13, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Twin Cities radiology group joins consortium rather than sell to private equity
A Twin Cities radiology group has joined a national consortium of independent practices after deciding not to sell itself to private equity investors. Minneapolis Radiology Associates, which employs 26 physicians and runs six clinics, announced it will become part of Palmetto, Fla.-based Strategic Radiology Corp. last week.  “We recently concluded decisively that we are not interested in a private equity/venture capital relationship,” said Troy Roovers, CEO of Minneapolis Radiology Associates,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 13, 2018 Category: American Health Authors: Katharine Grayson Source Type: news

Twin Cities radiology group joins consortium rather than sell to private equity
A Twin Cities radiology group has joined a national consortium of independent practices after deciding not to sell itself to private equity investors. Minneapolis Radiology Associates, which employs 26 physicians and runs six clinics, announced it will become part of Palmetto, Fla.-based Strategic Radiology Corp. last week.  “We recently concluded decisively that we are not interested in a private equity/venture capital relationship,” said Troy Roovers, CEO of Minneapolis Radiology Associates,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 13, 2018 Category: Biotechnology Authors: Katharine Grayson Source Type: news

Biolase CEO Flynn steps down | Personnel Moves – April 13, 2018
Biolase (NSDQ:BIOL) said this week its CEO Harold Flynn has resigned from the company to pursue other interests, and that current CFO John Beaver will step in to act as interim CEO. The transition will be made immediately, the Irvine, Calif.-based company said. “I would like to thank Harold for the leadership and commitment he has demonstrated over the last three years.  We are grateful for his contributions to product quality and for his steadfast dedication to Biolase.  We thank him for his continued support and wish him all the best in this new phase of his professional career. We are pleased to hav...
Source: Mass Device - April 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Biolase Conventus Orthopaedics Endotronix Inc. Frequency Therapeutics General Electric Henry Schein Inc. mckeonproducts nsfhealthsciencescertification Omnicell Inc. PerkinElmer Inc. personnel-moves Source Type: news

Elekta Expands the MOSAIQ Ecosystem of Complementary Applications With Strategic Investment in PalabraApps
Enhanced collaboration designed to advance Elekta's clinical workflow productivity and mobility offerings ATLANTA, April 12, 2018 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) today announced that it is making a strategic investment i... Devices, Oncology, Venture Capital Elekta, PalabraApps, MOSAIQ, radiotherapy, radiosurgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 12, 2018 Category: Pharmaceuticals Source Type: news

These 9 Bay Area venture-backed businesses hit $100M or more in their Q1 exits
Exits by venture-backed companies in the Bay Area remained relatively weak in the first quarter, despite a strong stock market and a big infusion of corporate cash from newly enacted federal tax breaks. The number of VC-backed businesses from the region that either went public or were sold dropped to 62 in this year's Q1, compared to 65 in the comparable quarter last year, according to a report this week from PitchBook Data and the National Venture Capital Association. The dollar value of those… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 11, 2018 Category: Biotechnology Authors: Cromwell Schubarth Source Type: news

These 9 Bay Area venture-backed businesses hit $100M or more in their Q1 exits
Exits by venture-backed companies in the Bay Area remained relatively weak in the first quarter, despite a strong stock market and a big infusion of corporate cash from newly enacted federal tax breaks. The number of VC-backed businesses from the region that either went public or were sold dropped to 62 in this year's Q1, compared to 65 in the comparable quarter last year, according to a report this week from PitchBook Data and the National Venture Capital Association. The dollar value of those… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 11, 2018 Category: American Health Authors: Cromwell Schubarth Source Type: news

These 9 Bay Area venture-backed businesses hit $100M or more in their Q1 exits
Exits by venture-backed companies in the Bay Area remained relatively weak in the first quarter, despite a strong stock market and a big infusion of corporate cash from newly enacted federal tax breaks. The number of VC-backed businesses from the region that either went public or were sold dropped to 62 in this year's Q1, compared to 65 in the comparable quarter last year, according to a report this week from PitchBook Data and the National Venture Capital Association. The dollar value of those… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 11, 2018 Category: Pharmaceuticals Authors: Cromwell Schubarth Source Type: news

RubrYc Therapeutics Completes $10M Million Series A Financing
SAN RAMON, Calif., April 11, 2018 -- (Healthcare Sales & Marketing Network) -- RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventur... Biopharmaceuticals, Venture Capital RubrYc Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2018 Category: Pharmaceuticals Source Type: news

Somatus Raises $11 Million in Series B Financing
Innovative Kidney Care Company works with Health Systems and Payers to enable value-based care for CKD and ESRD populations VIENNA, Va., April 11, 2018 -- (Healthcare Sales & Marketing Network) -- Somatus, an innovative care delivery and management com... Devices, Venture Capital Somatus, Chronic Kidney Disease, End Stage Renal Disease, dialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2018 Category: Pharmaceuticals Source Type: news

Maryland companies raise more than $400M of venture capital for second straight quarter
Maryland companies raised $406 million from venture capitalists in the first quarter of 2018, almost double what they raised the prior year. There were 16 deals involving Maryland companies in the three-month period, according to the PwC/CB Insights MoneyTree Report released Wednesday. The number of deals was five fewer than during the same period a year ago and the same as in the fourth quarter. The total dollar amount was up 99 perce nt from $203.8 million a year ago and down 1.3 percent from $411.3… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 11, 2018 Category: Pharmaceuticals Authors: Holden Wilen Source Type: news

Maryland companies raise more than $400M of venture capital for second straight quarter
Maryland companies raised $406 million from venture capitalists in the first quarter of 2018, almost double what they raised the prior year. There were 16 deals involving Maryland companies in the three-month period, according to the PwC/CB Insights MoneyTree Report released Wednesday. The number of deals was five fewer than during the same period a year ago and the same as in the fourth quarter. The total dollar amount was up 99 perce nt from $203.8 million a year ago and down 1.3 percent from $411.3… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 11, 2018 Category: Biotechnology Authors: Holden Wilen Source Type: news

Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner
RESEARCH TRIANGLE PARK, N.C., April 10, 2018 -- (Healthcare Sales & Marketing Network) -- Pappas Capital announced today that Thomas P. "Tom" Mathers has joined the firm as a partner. Mathers previously served as CEO of CoLucid Pharmaceuticals (... Biopharmaceuticals, Venture Capital, Personnel Pappas Capital (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 10, 2018 Category: Pharmaceuticals Source Type: news

MedImmune spinoff leads Greater Washington to stellar VC funding quarter
The D.C. area saw its biggest first quarter in startup funding in at least 16 years, with companies raking in more than $473.3 million in venture capital with the biotech and software sectors leading the way, according to data provided by PitchBook. The huge dollar haul also makes it the second-largest single quarter since the second quarter of 2011, when the region saw about $719.3 million in venture funding. The region also saw a strong close to 2017, with $447 million raised in the fourth quarter. So… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 10, 2018 Category: American Health Authors: Andy Medici Source Type: news

Optum ’s VC arm joins in $12M round for in-home lab testing startup
The venture capital arm of UnitedHealth Group Inc. ’s Optum unit has joined in a $12 million round of funding for a startup that lets people order lab tests and submit samples from home. Optum Ventures and Chinese venture capital firm Qiming Venture Partners led the investment in Ireland-based LetsGetChecked. The startup’s customers can request tests that screen for conditions ranging from sexually transmitted infections to cancer, according to its website. The company has a network of lab partners… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2018 Category: American Health Authors: Katharine Grayson Source Type: news

Optum ’s VC arm joins in $12M round for in-home lab testing startup
The venture capital arm of UnitedHealth Group Inc. ’s Optum unit has joined in a $12 million round of funding for a startup that lets people order lab tests and submit samples from home. Optum Ventures and Chinese venture capital firm Qiming Venture Partners led the investment in Ireland-based LetsGetChecked. The startup’s customers can request tests that screen for conditions ranging from sexually transmitted infections to cancer, according to its website. The company has a network of lab partners… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Katharine Grayson Source Type: news

Eidos Therapeutics completes $64M Series B financing
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials SAN FRANCISCO, April 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eidos Thera... Biopharmaceuticals, Venture Capital Eidos Therapeutics, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news

Sofinnova Partners launches $340m healthcare crossover fund
Sofinnova Partners said today it launched the $340 million (EU €275 million), life sciences-focused Sofinnova Crossover I fund which aims to invest in both public and private companies. The Paris-based venture capital firm said that the $340 million raise was above the fund’s first close target of $310 million (EU €250 million). The newly launched fund will look to invest in both biopharmaceutical and medical device companies. “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the y...
Source: Mass Device - April 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Sofinnova Partners Source Type: news

Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
Financing round led by Nextech Invest Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, Conn., April 4, 2018 -- (Healthcare Sales & Marketing Network) -- Arvinas LLC, a private biotechnology compa... Biopharmaceuticals, Venture Capital, Personnel Arvinas, Proteolysis Targeting Chimeras (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 4, 2018 Category: Pharmaceuticals Source Type: news

Brainomix Secures £7m ($9.8m) Investment to Tackle Strokes With AI
Brainomix builds on partnership with Boehringer Ingelheim for AI-assisted fast treatment of stroke victims in latest venture round. OXFORD, England, April 3, 2018 -- (Healthcare Sales & Marketing Network) -- Brainomix, a medical imaging company using a... Devices, Neurology, Venture Capital Brainomix, Boehringer Ingelheim, stroke, e-ASPECTS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2018 Category: Pharmaceuticals Source Type: news

Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
The Series A financing will support further development of the Company's pipeline of transformative dry powder drugs for pulmonary diseases and conditions. AUSTIN, Texas, April 3, 2018 -- (Healthcare Sales & Marketing Network) -- TFF Pharmaceuticals, I... Biopharmaceuticals, Venture Capital TFF Pharmaceuticals, Thin Film Freezing (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2018 Category: Pharmaceuticals Source Type: news

Inari Medical raises $27m
Inari Medical said today it closed a $27 million Series C round of financing, with funds slated to support commercialization of its FlowTriever and ClotTriever catheters designed for the treatment of venous thromboembolisms. Irvine, Calif.-based Inari’s ClotTriever device is designed to remove blood clots from large vessels in the peripheral vasculature, while it’s FlowTriever device is designed to retrieve pulmonary embolisms. The round was led by newly invested Gilde Healthcare and joined by all of Inari’s existing investors, including Versant Ventures and U.S. Venture Partners. Inari said tha...
Source: Mass Device - March 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Inari Medical Source Type: news

Inari Medical Announces Completion of $27 Million Series C Financing
IRVINE, Calif., March 29, 2018 -- (Healthcare Sales & Marketing Network) -- Inari Medical, Inc., announced today the close of a Series C financing totaling $27.0 million. The financing was led by new investor Gilde Healthcare and was joined by all of Ina... Devices, Interventional, Venture Capital Inari Medical, FlowTriever, ClotTriever, venous thromboembolism, thrombectomy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2018 Category: Pharmaceuticals Source Type: news

Singlera Genomics Raises $60 Million in Series A+ Financing
LA JOLLA, Calif., March 27, 2018 -- (Healthcare Sales & Marketing Network) -- Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, today announced that it has successfully secured a US$60 million Seri... Diagnostics, Venture Capital Singlera Genomics, non-invasive genetic diagnosis, single cell DNA sequencing (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2018 Category: Pharmaceuticals Source Type: news

TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers CAMBRIDGE, Mass., March 21, 2018 -- (Healthcare Sales & Marketing Network) -- TCR2 Therapeutics ... Biopharmaceuticals, Oncology, Venture Capital TCR2 Therapeutics, T cell therapies, TRuC platform (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2018 Category: Pharmaceuticals Source Type: news

Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures
TissueCypher® Barrett's Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Cancer PITTSBURGH, March 21, 2018 -- (Healthcare Sales & Marketing Network) -- Cernostics, a privately-held company focused on delivering next... Diagnostics, Oncology, Venture Capital Cernostics, TissueCypher, Barrett's Esophagus, esophageal cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2018 Category: Pharmaceuticals Source Type: news

UNITY Biotechnology, Inc. Completes $55 Million Series C Financing
Proceeds to Support Advancement of Pipeline into Clinical Studies SAN FRANCISCO, March 19, 2018 -- (Healthcare Sales & Marketing Network) -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics t... Biopharmaceuticals, Venture Capital UNITY Biotechnology, senolytic medicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 19, 2018 Category: Pharmaceuticals Source Type: news

TAE Life Sciences raises $40m for neutron beam cancer treatment
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers. The newly launched Foothill Ranch, Calif.-based company, which operates as a subsidiary of fusion energy company TAE Technologies, is developing neutron beam technology intended for Boron Neutron Capture Therapy. As part of the company’s launch, it announced that it is partnering with Chinese BNCT company Neuboron Medtech, and that its first neutron beam system will be delivered to Neuboron fo...
Source: Mass Device - March 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology taelifesciences Source Type: news

TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding
Company Becomes First to License TAE Technologies' Accelerator-based Beam Technology for Clinical Investigation FOOTHILL RANCH, Calif., March 12, 2018 -- (Healthcare Sales & Marketing Network) -- TAE Life Sciences, a medical technology company develop... Devices, Oncology, Venture Capital, Personnel TAE Life Sciences, neutron beam, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 12, 2018 Category: Pharmaceuticals Source Type: news

Vectorius Medical Technologies raises $10m for V-Lap wireless implantable heart monitor
Vectorious Medical Technologies reportedly raised nearly $10 million for the V-Lap implantable wireless heart monitor it’s developing. Tel Aviv-based Vectorius said the $9.5 million Series B round was led by Boston venture capital shop Broadview Ventures and China’s GEOC, joined by individual investors, Globes reported. The round included a $2.2 million grant from the European Union’s Horizon 2020 R&D program and the Israel Innovation Authority. Vectorius plans to use the proceeds to hire more workers as it ramps up to clinical trials ahead of a bid for CE Mark approval in the E.U., accordin...
Source: Mass Device - March 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat Vectorious Medical Technologies Source Type: news

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Lead investor Venrock joined by Celgene, Lightstone and DROIA Markus Renschler, M.D., joins as CEO, from Celgene Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for o... Biopharmaceuticals, Oncology, Venture Capital Cyteir Therapeutics, RAD51 transport (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 8, 2018 Category: Pharmaceuticals Source Type: news

Hoth Therapeutics Inc. Announces Completion of Series A Financing And Looks to Broaden Its Product Pipeline
NEW YORK, March 7, 2018 -- (Healthcare Sales & Marketing Network) -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from in... Biopharmaceuticals, Dermatology, Venture Capital Hoth Therapeutics, atopic dermatitis, eczema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 7, 2018 Category: Pharmaceuticals Source Type: news

CARsgen Completed $60 Million Pre-C Financing Framework Agreements
SHANGHAI, March 2, 2018 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a leading immune-oncology company focusing on the development of CAR-T therapies, today announces it has entered into a Pre-C financing framework agreement with rec... Biopharmaceuticals, Oncology, Venture Capital CARsgen Therapeutics, CAR-T therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2018 Category: Pharmaceuticals Source Type: news

Ex-Siemens Healthcare VC sues for retaliatory firing
A former venture capitalist with the healthcare operation at Siemens (NYSE:SI) sued the company last year, alleging that he was fired in retaliation for blowing the whistle on an alleged extortion attempt. Andrew Jay’s 14-year tenure in the German industrial conglomerate’s Boston venture shop ended in November 2017, when he declined to accept a demotion he alleges was made after he told the Siemens compliance department of a contractor’s alleged attempt to strong-arm a startup company Siemens was considering for an investment. Formerly a managing partner and VP, Jay’s team in the summer of 2016...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Diagnostics Funding Roundup Legal News Siemens Venture Capital/Private Equity Source Type: news

Report: Medtech faces 2018 challenges, FDA a bright spot
Financial trends for the medical device industry last year point to a continuing series of challenges for large and small companies alike in 2018, ranging from a tightening M&A landscape to an even tighter funding scene – with the FDA making a surprise appearance as a potential bright spot. According to the Pharma, Biotech and Medtech 2017 in Review report from EP Vantage, the editorial arm of life science market researcher Evaluate, the trends of 2017 augur worst for smaller medtech enterprises. “In medtech the funding crunch still exists for small companies,” Elizabeth Cairns, author of the report&r...
Source: Mass Device - February 28, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Wall Street Beat Evaluate Source Type: news

Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies
Founded by pioneers in the field of synthetic biology, Senti Biosciences' platform enables the design of adaptive therapies for challenging diseases. Series A round led by prominent investment firm New Enterprise Associates (NEA) along with other top inves... Biopharmaceuticals, Venture Capital Senti Biosciences, synthetic biology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2018 Category: Pharmaceuticals Source Type: news

This week in N.Y.C. funding news: Kallyope, Team Pay, Serial Box, Tunity
Every so often, it's worth reminding Bizjournal readers who the major seed investors are in N.Y.C. Considering there was a steep decline in early-stage funding in the previous quarter, entrepreneurs would be wise to familiarize themselves on which investors are the most active. Pitchbook is generous to keep track of that information. Here are the top eight venture capital firms that tend to i nk the most seed round deals for New York-based companies, dating back to 2014 with deal tally (as of… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 23, 2018 Category: Pharmaceuticals Authors: Anthony Noto Source Type: news

This week in N.Y.C. funding news: Kallyope, Team Pay, Serial Box, Tunity
Every so often, it's worth reminding Bizjournal readers who the major seed investors are in N.Y.C. Considering there was a steep decline in early-stage funding in the previous quarter, entrepreneurs would be wise to familiarize themselves on which investors are the most active. Pitchbook is generous to keep track of that information. Here are the top eight venture capital firms that tend to i nk the most seed round deals for New York-based companies, dating back to 2014 with deal tally (as of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 23, 2018 Category: Biotechnology Authors: Anthony Noto Source Type: news

Hoth Therapeutics Inc. Announces Completion of Series A Financing
NEW YORK, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from in... Biopharmaceuticals, Dermatology, Venture Capital Hoth Therapeutics, atopic dermatitis, eczema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Kallyope Inc. Announces $66M Series B Financing to Advance Programs Targeting the Gut-Brain Axis
All existing backers including Lux Capital, The Column Group, and Polaris Partners joined by new investors Euclidean Capital and Two Sigma Ventures Progress in building a comprehensive map of gut-brain circuits and identification of therapeutic opportun... Biopharmaceuticals, Neurology, Venture Capital Kallyope, gut-brain axis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news